NASDAQ:CASICASI Pharmaceuticals Stock Price, Forecast & News

$2.71

+0.02 (+0.74 %)

(As of 05/26/2020 03:41 PM ET)

Add

Compare

Today's Range

$2.59

Now: $2.71▼

$2.78

50-Day Range

$1.66

MA: $1.89▼

$2.69

52-Week Range

$1.15

Now: $2.71▼

$3.82

Volume329,673 shs

Average Volume278,008 shs

Market Capitalization$273.49 million

P/E RatioN/A

Dividend YieldN/A

Beta0.81

CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
CASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.50, CASI Pharmaceuticals has a potential upside of 29.2% from its current price of $2.71.
Amount of Analyst Coverage
CASI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
CASI Pharmaceuticals has received 177 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
CASI Pharmaceuticals has received 180 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
CASI Pharmaceuticals has received 50.42% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote “Outperform” if you believe CASI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
CASI Pharmaceuticals does not currently pay a dividend.
Dividend Growth
CASI Pharmaceuticals does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CASI Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,284,788.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 24.29% of the stock of CASI Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 21.55% of the stock of CASI Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for CASI Pharmaceuticals are expected to decrease in the coming year, from ($0.30) to ($0.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CASI Pharmaceuticals is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CASI Pharmaceuticals is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CASI Pharmaceuticals has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.80 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CASI

Previous Symbol

CUSIPN/A

CIK895051

Webwww.casipharmaceuticals.com

Phone240-864-2600

Debt

Debt-to-Equity RatioN/A

Current Ratio7.93

Quick Ratio7.66

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.13 million

Price / Sales66.22

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.76 per share

Price / Book3.57

Profitability

EPS (Most Recent Fiscal Year)($0.42)

Net Income$-46,030,000.00

Net MarginsN/A

Return on Equity-51.65%

Return on Assets-37.72%

Miscellaneous

Employees124

Outstanding Shares100,920,000

Market Cap$273.49 million

Next Earnings Date8/14/2020 (Estimated)

OptionableNot Optionable

Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.

CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

How has CASI Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

CASI Pharmaceuticals' stock was trading at $1.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CASI shares have increased by 66.3% and is now trading at $2.71. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CASI Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CASI Pharmaceuticals.

When is CASI Pharmaceuticals' next earnings date?

CASI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for CASI Pharmaceuticals.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals Inc (NASDAQ:CASI) posted its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.09) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.02. The biotechnology company had revenue of $3.41 million for the quarter, compared to analyst estimates of $0.79 million. View CASI Pharmaceuticals' earnings history.

What price target have analysts set for CASI?

1 brokerages have issued 1 year target prices for CASI Pharmaceuticals' stock. Their forecasts range from $3.50 to $3.50. On average, they expect CASI Pharmaceuticals' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price. View analysts' price targets for CASI Pharmaceuticals.

Has CASI Pharmaceuticals been receiving favorable news coverage?

Headlines about CASI stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. CASI Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutCASI Pharmaceuticals.

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 2,310,000 shares, a decrease of 5.3% from the April 30th total of 2,440,000 shares. Based on an average trading volume of 231,000 shares, the short-interest ratio is presently 10.0 days. Currently, 5.3% of the shares of the stock are short sold. View CASI Pharmaceuticals' Current Options Chain.

Who are some of CASI Pharmaceuticals' key competitors?

Some companies that are related to CASI Pharmaceuticals include Sorrento Therapeutics (SRNE), Compugen (CGEN), Orchard Therapeutics (ORTX), Krystal Biotech (KRYS), Proteon Therapeutics (PRTO), Cellectis (CLLS), Atara Biotherapeutics (ATRA), BioCryst Pharmaceuticals (BCRX), BAVARIAN NORDIC/S (BVNRY), Replimune Group (REPL), Adaptimmune Therapeutics (ADAP), Aerie Pharmaceuticals (AERI), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY) and Vericel (VCEL). View all competitors.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include Caladrius Biosciences (CLBS), Catalyst Pharmaceuticals (CPRX), Frontier Communications (FTR), Bank of Hawaii (BOH), Celsion (CLSN), Energy Transfer LP Unit (ET), InterDigital Wireless (IDCC), Novavax (NVAX), Rigel Pharmaceuticals (RIGL) and Abeona Therapeutics (ABEO).

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the following people:

Dr. Wei-Wu He, Chairman & CEO (Age 54)
Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 50)
Dr. Wei Zhang Ph.D., Pres of CASI (Beijing) Pharmaceuticals Co., Ltd (Age 60)
Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)
Ms. Sara B. Capitelli, VP of Fin. & Principal Accounting Officer (Age 53)

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (3.22%), Ikarian Capital LLC (1.03%), State Street Corp (0.90%), Geode Capital Management LLC (0.70%), Bank of New York Mellon Corp (0.17%) and Vident Investment Advisory LLC (0.08%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman and Wei-Wu He. View institutional ownership trends for CASI Pharmaceuticals.

Which major investors are selling CASI Pharmaceuticals stock?

CASI stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, BlackRock Inc., and IHT Wealth Management LLC. View insider buying and selling activity for CASI Pharmaceuticals.

Which major investors are buying CASI Pharmaceuticals stock?

CASI stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, WINTON GROUP Ltd, Geode Capital Management LLC, SG Americas Securities LLC, Vident Investment Advisory LLC, Wellesley Investment Partners LLC, Alliancebernstein L.P., and JPMorgan Chase & Co.. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, and Wei-Wu He. View insider buying and selling activity for CASI Pharmaceuticals.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $2.71.

How big of a company is CASI Pharmaceuticals?

CASI Pharmaceuticals has a market capitalization of $273.49 million and generates $4.13 million in revenue each year. The biotechnology company earns $-46,030,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe.

What is CASI Pharmaceuticals' official website?

The official website for CASI Pharmaceuticals is www.casipharmaceuticals.com.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff